AegirBio is excited to present data at ECTRIMS 2023 in Milan from an observational trial carried out in collaboration with the Rocky Mountain Multiple Sclerosis Research Group.
We will share new findings on how patients' immune systems can influence the clearance rate of intact natalizumab. Our data also illustrates saliva’s great potential for non-invasive monitoring of patient natalizumab levels.
Stop by Poster P314 during poster session 1 if you would like to learn more or set up a meeting.
We are focused on therapeutic drug monitoring of biologic therapies in the autoimmune, oncology and neurology space. Biologic drug concentrations vary widely between patients, leading to unnecessary side effects and suboptimal clinical outcomes. By tracking drug levels in individual patients, these high cost treatments can be personalized to improve treatment results and unlock savings for healthcare systems. Aegirbio is setting new standards in this field by pioneering Point of Care and Point of Need tests that can provide results within minutes.